International CML Foundation

23/12/2025

Every year, 81,000 people worldwide are newly diagnosed with CML. Behind each number is a person, a family, a story.

That's why we climb – to ensure everyone diagnosed with CML has access to the best possible care and treatment, no matter where they are in the world.

Support our mission: climb-for-a-cure.raiselysite.com

22/12/2025

Watch Our Year in Review: Reflections from Professor Jorge Cortes

In his opening remarks at the ESH-iCMLf Annual John Goldman Conference on Chronic Myeloid Leukemia: Biology and Therapy, Professor Jorge Cortes reflects on the past year in CML - set against 25 years of progress since the introduction of imatinib.

He reviews how the field continues to evolve, the role of the iCMLf in supporting global access to expert care, and the collaborative research efforts now shaping the next phase of CML science.

A thoughtful overview of where CML stands today, and the questions guiding the year ahead.

Watch the recording here: https://buff.ly/ncJVXVB

19/12/2025

This holiday season, give the gift that keeps giving!

Our climbers are training hard to take on the Avenue of Volcanoes in February, all to support better treatment and care for people living with CML around the world.

Your donation today will help fund critical research, improve access to care, and bring us closer to a cure. Support a climber and make a difference this season: climb-for-a-cure.raiselysite.com

18/12/2025

As we close out 2025, we’re looking back on a year shaped by global collaboration and scientific progress across the CML community.

From expanding our education programs, to launching new clinical tools, to marking 25 years of TKI therapy, this year reaffirmed what is possible when clinicians, researchers, advocates and partners work together.

Highlights from 2025 include:
- Honouring 25 Years of TKIs with a global campaign, digital timeline, and a World CML Day film capturing voices from around the world.
- Strengthening clinical practice through Regional Discussion Groups, iCMLf Conversations, and our expanded Paper & Session Summary series.
- Launching the new Clinical Trial Hub, making trial information easier to navigate for both physicians and patients.
- Hosting major events including the ESH-iCMLf 27th Annual John Goldman Conference and our first iCMLf Forum in Saudi Arabia.

A huge thank you to everyone who contributed, shared insights, and supported this work.
Together, we continue to improve outcomes for people living with CML worldwide.

16/12/2025

Meet Yunus Borowczak! He is one of our amazing climbers, trekking for better CML treatment in February.

Yunus has been living with CML for over 10 years.
"Over time, I’ve become more and more involved in advocacy work. Personally, I want to fundraise to improve the daily lives of every single CML patient out there. My dream is to be cured one day, and I’m deeply grateful to everyone who supports the CML community.”

Support him on this mission and donate for more CML awareness and research worldwide: climb-for-a-cure.raiselysite.com

15/12/2025

Third ASH Highlight now live

We’re wrapping up our ASH coverage with the Oral Abstract Session on CML clinical and epidemiological studies, focusing on new and emerging therapies to improve patient outcomes.

This session brought forward important data on novel allosteric inhibitors, asciminib in frontline and second-line settings, risk-adapted treatment strategies, and the ongoing challenges in blast-phase CML.

If you want a clear, practice-focused overview of what this means for CML care now and in the years ahead, you can read the full summary here:

🔗 https://buff.ly/OX5CeAf

12/12/2025

Meet Kendra Sweet! She is one of our dedicated climbers taking on Ecuador's Avenue of Volcanoes in February.

“My career has been dedicated to advancing treatment for people with CML. I am fundraising to continue our advancements, and to enable people from all around the world to gain access to life-saving treatments.”

Support her journey and help us advance CML research and care worldwide: climb-for-a-cure.raiselysite.com

10/12/2025

As we mark 25 years since imatinib first transformed outcomes in CML, this new feature in AJMC looks back at the moment everything changed – and what still lies ahead.

In an in-depth interview, iCMLf Chairman Professor Jorge Cortes reflects on:
- The early STI-571 trials and the shift from interferon to targeted therapy
- How imatinib reshaped survival, quality of life, and expectations for people with CML
- Ongoing challenges around resistance, combinations, and treatment-free remission
- Why continued investment in cancer research still matters

A powerful reminder of how far we have come in CML – and why we cannot afford to lose momentum.

Read the full article in AJMC here:

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.

09/12/2025

Day 2 ASH Highlights now live.

Today we’re covering the Education Spotlight Session: The changing face of CML - with fresh insights on frontline therapy choices, treatment-free remission, and what truly personalised CML care looks like in 2025 and beyond.

If you want a clear, practice-focused overview of the latest thinking from leading experts, you can read the full summary here:

https://buff.ly/OX5CeAf

08/12/2025

Here are our selection of CML Papers for November curated by Prof. Tim Hughes.
Highlights include:

1️⃣ Efficacy, safety and predictive biomarker of third-generation tyrosine kinase inhibitors with azacitidine in myeloid blast phase of chronic myeloid leukemia
Bao M et al. Cancer, November 2025 – open access publication
https://buff.ly/VKbp6K7

2️⃣ Real-world decline in survival with poor guideline adherence in chronic myeloid leukemia care
Metsemakers SJJPM et al. Blood Cancer J, November 2025
– open access publication
https://buff.ly/jdFbwVv

3️⃣ In-depth analysis for tyrosine kinase inhibitor-driven real-world management of 201 CML patients using TFR
Micu ML et al. Front Pharmacol, November 2025 – open access publication
https://buff.ly/tmZSUp2

4️⃣ HLA diversity is associated with tyrosine kinase inhibitor response and treatment-free remission in chronic myeloid leukemia
Toulemonde C et al. Hemasphere, November 2025 – open access publication
https://buff.ly/NeMKv3r

📖 Explore the full list of papers on our website:
https://buff.ly/9DoiXTp

08/12/2025

We’re pleased to share the first of our CML highlights from the 67th American Society of Hematology Annual Meeting.

This overview of the Oral Abstract Session on CML clinical and epidemiological research brings together emerging insights into the molecular drivers of response, resistance, relapse, and treatment-free remission. The session covered advances in genomic profiling, single-cell sequencing, transcriptomics, machine learning, and integrated MRD monitoring — each offering new perspectives on how and why CML behaves differently across patients.

We were also proud to see new data from the iCMLf Genomics Alliance, presented as part of this session, contributing large-scale evidence on the clinical relevance of pathogenic variants at diagnosis.

Read the full summary here:
https://www.cml-foundation.org/about-us/news/2406-cml-summaries-of-the-67th-ash-annual-meeting.html